While initially very responsive to both chemotherapy and radiation therapy, the majority of patients will have recurrent disease or become refractory to treatment. The 5-year survival of patients with small cell lung cancer is only 5%. The staging of small cell lung cancer is divided into ...
Non-small-cell lung cancer (NSCLC) is one of the most frequent cancer types and is responsible for the majority of cancer-related deaths worldwide. The management of NSCLC has improved considerably, especially in the past 10 years. The systematic screeni
lung cancer; small cell lung cancer; treatment Abstract: Lung cancer was relatively uncommon at the turn of the 20th century, and has increased in prevalence at alarming rates, particularly because of the augmented trend in smoking, so that it is now the most common cause of cancer death in...
Although small cell lung cancer (SCLC) is treated as a homogeneous disease, biopsies and preclinical models reveal heterogeneity in transcriptomes and morphology. SCLC subtypes were recently defined by neuroendocrine transcription factor (NETF) expressio
: Stage III unresectable locally advanced non-small cell lung cancer (NSCLC) is a complex disease group with poor long-term survival. Clinical data suggests curative intent concurrent chemoradiotherapy (CCRT) is superior to a sequential (SCRT) approach but comes with additional toxicities. We report...
(brigatinib) as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. ALUNBRIG is a next-generation tyrosine kinase inhibitor (TKI) that was designed to target...
Central nervous system (CNS) metastases are common in non-small-cell lung cancer (NSCLC) and associated with poor prognosis and high disease burden. Effective options are needed to treat CNS metastases, and delay or prevent their formation. For epidermal growth factor receptor mutation-positive (...
Takeda Receives Positive CHMP Opinion for ALUNBRIG®(brigatinib) as a First-Line Treatment for ALK+ Non-Small Cell Lung Cancer –If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ...
Small-cell lung cancer (SCLC), an aggressive neuroendocrine tumor with early dissemination and dismal prognosis, accounts for 15–20% of lung cancer cases and∼200,000 deaths each year. Most cases are inoperable, and biopsies to investigate SCLC biology are rarely obtainable. Circulating tumor c...
Small cell lung cancer (SCLC), which accounts for 15% of lung malignancies, has a poor prognosis [1]. SCLC is often discovered after it is already at an advanced, unresectable stage, and treatment is thus limited to anticancer drug therapy. While novel tyrosine kinase inhibitors and immune ...